Skip to main content
Premium Trial:

Request an Annual Quote

Alacris Attains Illumina CSPro Certification for NGS

NEW YORK (GenomeWeb News) – Alacris Theranostics today said that is has gained Illumina CSPro certification for next-generation sequencing.

Illumina CSPro is a collaborative service provider partnership aimed at providing high quality data for genetic analysis applications, and applicants undergo a two-phase process that includes minimum data generation, data certification, and an onsite audit of the facility and processes.

Based in Berlin, Alacris specializes in personalized medicine for cancer patient diagnosis, treatment, and stratification, it said on its website. It uses a systems biology approach, called ModCell, developed at the Max Planck Institute for Molecular Genetics and licensed to Alacris. The approach is based on next-generation sequencing to provide information about the genome and transcriptome, and incorporates kinetic pathway information, and mutation and drug databases.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.